1. Home
  2. LOCO vs HELP Comparison

LOCO vs HELP Comparison

Compare LOCO & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

N/A

Current Price

$11.28

Market Cap

331.3M

ML Signal

N/A

HELP

Cybin Inc. Common Stock

N/A

Current Price

$5.74

Market Cap

281.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LOCO
HELP
Founded
1980
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.3M
281.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
LOCO
HELP
Price
$11.28
$5.74
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$14.50
$95.00
AVG Volume (30 Days)
130.0K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
16.22
N/A
EPS
0.68
N/A
Revenue
$401,701,000.00
N/A
Revenue This Year
$5.42
N/A
Revenue Next Year
$1.67
N/A
P/E Ratio
$16.16
N/A
Revenue Growth
5.68
N/A
52 Week Low
$8.29
$5.25
52 Week High
$11.74
$8.55

Technical Indicators

Market Signals
Indicator
LOCO
HELP
Relative Strength Index (RSI) 58.67 41.02
Support Level $10.16 N/A
Resistance Level $11.44 $7.28
Average True Range (ATR) 0.27 0.66
MACD 0.03 -0.19
Stochastic Oscillator 82.69 17.65

Price Performance

Historical Comparison
LOCO
HELP

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: